CORT241220P60000
- 4.60
- -1.94-29.66%
Corcept Therapeutics Newsroom
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating
Truist Financial Keeps Their Buy Rating on Corcept Therapeutics (CORT)
A Quick Look at Today's Ratings for Corcept Therapeutics(CORT.US), With a Forecast Between $67 to $80
Corcept Therapeutics Analyst Ratings
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating
Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Corcept Therapeutics Analyst Ratings
H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $80
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $76
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $78
Buy Rating Affirmed for Corcept Therapeutics Amid Strong Financials and Promising Clinical Trials
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating
Truist Financial Gives a Buy Rating to Corcept Therapeutics (CORT)
Corcept Therapeutics Is Maintained at Overweight by Piper Sandler
Corcept Therapeutics Analyst Ratings
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $67
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $78
Buy Rating Affirmed for Corcept Therapeutics on Strong Financials and Promising Drug Pipeline
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $78
A Quick Look at Today's Ratings for Corcept Therapeutics(CORT.US), With a Forecast Between $38 to $45